Cargando…
Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
Immune checkpoint inhibitors (ICIs) expanded the therapeutic options for several cancers. However, whether some special groups of patients including those with organ transplantation can receive ICIs remains unclear. In this report we presented an interesting case. A 54-year-old woman underwent kidne...
Autores principales: | Chen, Didi, Wu, Xinyi, Xie, Congying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187800/ https://www.ncbi.nlm.nih.gov/pubmed/34123796 http://dx.doi.org/10.3389/fonc.2021.646322 |
Ejemplares similares
-
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
por: Kwatra, Vineet, et al.
Publicado: (2017) -
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
por: Ong, Michael, et al.
Publicado: (2016) -
Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020) -
A case of cabozantinib therapy leading to complete remission for massive intra-intestinal bleeding and worsening metastatic sites following nivolumab and ipilimumab therapy
por: Ishida, Kyohei, et al.
Publicado: (2023) -
Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)